Novadaq Technologies Company Profile (NASDAQ:NVDQ)

Novadaq Technologies trades on the NASDAQ under the ticker symbol "NVDQ."

Novadaq Technologies Inc. (NASDAQ:NVDQ) posted its quarterly earnings results on Wednesday, May, 3rd. The company reported ($0.24) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.03. The business earned $21.08 million during the quarter, compared to analyst estimates of $20.12 million. Novadaq Technologies had a negative return on equity of 31.34% and a negative net margin of 55.26%. View Novadaq Technologies' Earnings History.

12 brokers have issued 12-month price objectives for Novadaq Technologies' shares. Their forecasts range from $7.00 to $18.00. On average, they expect Novadaq Technologies' stock price to reach $11.43 in the next twelve months. View Analyst Ratings for Novadaq Technologies.

Here are some recent quotes from research analysts about Novadaq Technologies stock:

• 1. According to Zacks Investment Research, "Novadaq Technologies Inc. develops, manufactures and markets real-time fluorescence imaging products for use in the operating room and other clinical settings. The company's key markets include plastic reconstructive, gastrointestinal, cardiac and general surgery. It provides SPY imaging systems which enables surgeons to the visualize blood flow in vessels, co-joined vessels and micro-vessels. Novadaq Technologies Inc. is headquartered in Mississauga, Canada. " (5/9/2017)
• 2. Stifel Nicolaus analysts commented, "We continue to believe the underlying value proposition of the larger NVDQ story remains unchanged. The combination of our high level of conviction in the company's highly differentiated and clinically relevant technology, a very solid balance sheet (at least 3-4 years of cash with revolver) with no need for near-term dilutive financing, and the shares' discounted valuation are enough, in our view, to continue recommending the shares... . In the long run, if these initiatives are even remotely successful, we believe it argues for a much higher value for the company, standalone or for potential strategic acquirers. On the basis of our new, now lower 2017 projections, adjusted down largely to reflect the impact of a new flexible capital acquisition model, we lower our TP to $10 (from $16)." (3/1/2017)

Novadaq Technologies saw a decrease in short interest during the month of April. As of April 28th, there was short interest totalling 5,516,517 shares, a decrease of 5.3% from the April 13th total of 5,828,140 shares. Based on an average trading volume of 299,834 shares, the short-interest ratio is currently 18.4 days.

Some companies that are related to Novadaq Technologies include BioTelemetry (BEAT), Heska Corp (HSKA), China Cord Blood Corp (CO), NeoGenomics (NEO), Natera (NTRA), Enzo Biochem (ENZ), InVitae Corp (NVTA), RadNet (RDNT), Miragen Therapeutics (MGEN), Alliance HealthCare Services (AIQ), Fluidigm (FLDM), Cytosorbents Corp (CTSO), VolitionRX Ltd (VNRX), Cancer Genetics (CGIX), Biocept (BIOC), HTG Molecular Diagnostics (HTGM), Check Cap Ltd (CHEK) and TrovaGene (TROV).

Novadaq Technologies' management team includes the folowing people:

• William A. MacKinnon, Chairman of the Board
• Rick Mangat Ph.D., President, Chief Executive Officer
• Roger Deck, Chief Financial Officer
• Lori Swalm, Vice President of Marketing
• Derrick Guo, General Counsel, Corporate Secretary
• Anthony F. Griffiths, Lead Independent Director
• Lisa N. Colleran, Director
• Karen A. Licitra, Director
• Patrice E. Merrin, Independent Director
• Thomas G. Wellner, Independent Director

Novadaq Technologies' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (9.79%), Janus Capital Management LLC (8.19%), Riverbridge Partners LLC (5.66%), FMR LLC (5.38%), Elk Creek Partners LLC (4.68%) and OppenheimerFunds Inc. (3.09%). View Institutional Ownership Trends for Novadaq Technologies.

Novadaq Technologies' stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Bellevue Group AG, Blair William & Co. IL, CWM LLC, Riverbridge Partners LLC, Goldman Sachs Group Inc., TCW Group Inc. and Janus Capital Management LLC. View Insider Buying and Selling for Novadaq Technologies.

Novadaq Technologies' stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., FMR LLC, Royce & Associates LP, Granite Investment Partners LLC, Bank of America Corp DE, C WorldWide Group Holding A S, Elk Creek Partners LLC and AXA. View Insider Buying and Selling for Novadaq Technologies.

Shares of Novadaq Technologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Novadaq Technologies stock can currently be purchased for approximately $7.42.